Intranasal Oxytocin and Enhancement of Team Cohesion

Completed · Phase 1 · Has a placebo group

Conditions studied: Unit Cohesion

In brief

This study attempts to identify the psychological, behavioral, physiological, and hormonal predictors and mechanisms of an individual's ability to develop cohesion in a group working together as a team; and examine if administration of the prosocial neuropeptide oxytocin enhances the development of team cohesion. Through a deeper understanding of the underlying psychobiological predictors and mechanisms of team cohesion, the prospective identification of individuals whose unique characteristics promote or inhibit the development of group cohesion will become possible.

Key facts

Study ID

NCT02302430

Run by

University of California, San Francisco

People needed

486

Starts

2015-10-01

Expected to finish

2019-05-31

Last updated by the study team

2019-08-05

Who can join

Age: 18 and older, up to 28. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age 18-28
• Speak English
• Ability to use a nasal spray

You may not qualify if…

• Positive urine pregnancy test
• History of psychiatric or neurologic disorder
• Use of illicit drugs in the past month
• History of moderate-severe alcohol use disorder as defined by DSM-V criteria
• Sensitivity to preservatives (in particular E 216, E 218 and chlorobutanol hemihydrate)
• Nasal obstruction, discharge, or bleeding
• Habitually drinks large volumes of water
• Taking testosterone, estrogen/progesterone supplement, or serotonin-1a receptor agonists/antagonists
• Currently meets Diagnostic and Statistical Manual-5 (DSM-V) criteria for severe major depressive disorder with suicidal thoughts or actions

Where it is running

• San Francisco VA Medical Center — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.